PMPRB Hearing Panel issues decision in Soliris case
A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc. The Panel has found that the price of Soliris (eculizumab) 10 mg/mL was and is excessive under sections 83 and 85 of the Patent Act. The Panel has ordered Alexion to pay to Her Majesty in right of Canada an amount calculated in accordance with Schedule A to this decision. The Hearing Panel has also ordered Alexion to lower the list price of Soliris in Canada as of September 20, 2017 to no higher than the lowest price in the seven comparator countries set out in the Patented Medicines Regulations.
The Patented Medicine Prices Review Board (PMPRB) is an independent quasi-judicial body that protects the interests of Canadian consumers by ensuring the prices of patented medicines sold in Canada are not excessive, and provides stakeholders with price, cost, and utilization information to help them make timely and knowledgeable drug pricing, purchasing, and reimbursement decisions.
Patentees must file price and sales information with the PMPRB at introduction, and twice a year afterward, for each strength of each dosage form of each patented medicine sold in Canada.
PMPRB staff review the prices patentees charge for each individual patented drug product sold in Canadian markets on an ongoing basis to ensure their prices are not excessive.
If the PMPRB Hearing Panel finds a patentee to be in breach of its reporting requirements, the Panel may order the patentee to provide the PMPRB with the required pricing and sales information.
Questions pertaining to the registry or the docket for this matter may be directed to:
Director, Board Secretariat
All other questions should be directed to:
PMPRB Media Relations
Report a problem or mistake on this page
- Date modified: